Search - tctmd.com

Displaying 241 - 260 of 524

Sort: Relevancy | Date

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Shelley Wood

May 25, 2022

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Opinion CV Team Dispatch

May 2022 News Roundup

L.A. McKeown

May 01, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

News Daily News

Infertility in Women Linked to Subsequent Risk of HFpEF

L.A. McKeown

April 19, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

Seasonal, but No Year-round, Protection With Flu Shots in HF: IVVE

News Conference News ACC 2022

Seasonal, but No Year-round Help for HF With Flu Shots: IVVE

Yael L. Maxwell

April 03, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Daily News

A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients

Caitlin E. Cox

March 31, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Study Touts Benefits of Exercise as Primary CVD Prevention in Older Adults

L.A. McKeown

February 15, 2022

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

News Industry News

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

February 02, 2022

Advertisement

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

May 2022 News Roundup

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Infertility in Women Linked to Subsequent Risk of HFpEF

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Seasonal, but No Year-round Help for HF With Flu Shots: IVVE

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 2022 News Roundup

A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Guideline-Directed Therapies Underused in Frail HF Patients

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

March 2022 News Roundup

FDA Approves Empagliflozin for Treatment of HFpEF

Study Touts Benefits of Exercise as Primary CVD Prevention in Older Adults

Modified Surgical MV Repair Stands Up to Replacement

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content